Robert Williams
Optometrist · Myrtle Beach, SCNPI 1417933078
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Coopervision Inc. at 26.7% of the total. Reporting peaked in 2022 at $738 and has fallen 70.2% since, to $220 in 2025.
Across 36 payments — averaging $68.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$660
- Alcon$444
- Optos, Inc.$325
- Bausch & Lomb, A Division Of Bausch Health US, LLC$193
- AbbVie$150
- Johnson & Johnson Surgical Vision, Inc.$147
- plus $550 from 8 others
Across 4 payments — averaging $4418.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$18K
What the payments were for
- Speaking & faculty fees$502%
- Food & beverage$2,28893%
- Entertainment$1325%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 8 | $660 |
| Alcon | 6 | $444 |
| Optos, Inc. | 4 | $325 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $193 |
| AbbVie(2 entities) | 4 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $147 |
| Astellas Pharma US Inc | 1 | $124 |
| Johnson & Johnson Vision Care, Inc. | 1 | $122 |
| Bausch & Lomb Americas Inc. | 1 | $96 |
| Maculogix, Inc. | 2 | $69 |
| Mallinckrodt Hospital Products Inc. | 1 | $66 |
| Oyster Point Pharma, Inc. | 2 | $38 |
| Novartis | 1 | $22 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$309
- Tecnis IOL$294
- MyDay Contact Lens$234
- TOTAL30$219
- OCT OPHTHALMOSCOPE$155
- NFC-700$155
- CATALYS SYSTEM$147
- VERITAS Vision System$147
- INFUSE$124
- Izervay$124
- Acuvue$122
- Multiple Brands Contact Lens$118
- DAILIES TOTAL1$104
How this compares
$2,470 in reported general payments places this provider in the 75th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $33,376 |
| Cyclosporine | 11 | $9,580 |
| Latanoprost | 127 | $1,128 |
| Fluorometholone | 16 | $952 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 57 | $716 |
| Prednisolone Acetate | 23 | $678 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 31 | $668 |
| Timolol Maleate | 30 | $232 |
| Ketorolac Tromethamine | 15 | $214 |
| Brimonidine Tartrate | 11 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $150 | $33,37633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Myrtle Beach
- Thomas WeshefskyMyrtle Beach$77K
- Amanda LeeMyrtle Beach$7K
- Lindsey AdamsMyrtle Beach$6K
- Tammy TullyMyrtle Beach$5K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.